Αρχειοθήκη ιστολογίου

Δευτέρα 24 Ιουλίου 2017

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Conditions:   BRAF V600E Mutation Present;   Papillary Craniopharyngioma Interventions:   Drug: Vemurafenib;   Drug: Cobimetinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2vCnQH1
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader